The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis | |
Fang Liu; Tao Jin; Lei Liu; Zhongzheng Xiang; Ruonan Yan; Hui Yang | |
刊名 | PLoS One
![]() |
2018 | |
卷号 | Vol.13 No.3页码:e0194733 |
ISSN号 | 1932-6203 |
URL标识 | 查看原文 |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/1823278 |
专题 | 四川大学 |
作者单位 | 1.Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China 2.The Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China 3.Department of Otolaryngology-Head and Neck Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China George Washington University Milken Institute of Public Health, UNITED STATES |
推荐引用方式 GB/T 7714 | Fang Liu,Tao Jin,Lei Liu,et al. The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis[J]. PLoS One,2018,Vol.13 No.3:e0194733. |
APA | Fang Liu,Tao Jin,Lei Liu,Zhongzheng Xiang,Ruonan Yan,&Hui Yang.(2018).The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis.PLoS One,Vol.13 No.3,e0194733. |
MLA | Fang Liu,et al."The role of concurrent chemotherapy for stage II nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A systematic review and meta-analysis".PLoS One Vol.13 No.3(2018):e0194733. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论